Summary of Teleflex Conference Call Company Overview - **Company**: Teleflex - **Industry**: Medical Technology Q1 Results - **Growth Performance**: Q1 growth was reported at -3.8%, adjusted for two less selling days, the growth was approximately -1.7% [3][4] - **Product Performance**: Strong performance noted in balloon pumps in The Americas and progress with Pallet and Baragel products [3][4] - **OEM Challenges**: OEM segment experienced negative growth due to a lost customer costing approximately $7 million and inventory management issues among key customers [5][6] Guidance and Growth Expectations - **Full Year Guidance**: Reiterated guidance of 1% to 2% growth for the year, with expectations of acceleration in the second half [7][10] - **Quarterly Projections**: Anticipated growth of 1% in Q2, 3.5% in Q3, and 6% in Q4, with a significant pickup expected due to the anniversary of the lost customer and additional selling days in Q4 [7][8][10] Tariff Impact - **Tariff Guidance**: Total tariff impact estimated at $55 million, with 50% attributed to China. The company is hopeful for exemptions for medical devices [11][13][15] - **Mitigation Strategies**: Strategies include improving USMCA compliance, pricing adjustments, and supply chain changes to mitigate tariff impacts [20][21] Business Separation Strategy - **Separation Rationale**: Decision to separate into two entities based on different capital allocation and growth strategies, aiming to unlock shareholder value [25][26] - **Growth Profiles**: One entity expected to grow at low single digits with mid-fifties gross margins, while Teleflex RemainCo projected to grow at over 6% with mid-sixties gross margins [27][28] Market Dynamics - **OEM Business Outlook**: Anticipated negative growth of 10-12% for the OEM segment in 2025, but expected to return to growth in 2026 [35][36] - **UroLift Challenges**: UroLift has faced pressure due to reimbursement changes, but improvements are expected as the reimbursement environment stabilizes [37][38] Acquisition Interest - **Interest in NewCo**: Significant inbound interest in NewCo assets from both financial and strategic parties, indicating strong market validation [41][42] - **Sale vs. Spin**: The decision on whether to sell or spin off NewCo will be based on what maximizes shareholder value [43][46] Product Performance Highlights - **Pallet Growth**: Pallet product grew approximately 30% in the previous year and continues to trend above initial growth expectations [59][60] - **Baragel Market Expansion**: Anticipated market expansion for Baragel with a new indication for post-radical prostatectomy spacing expected by the end of 2026, potentially adding $100 million to the addressable market [61][63][64] Conclusion - Teleflex is navigating a challenging environment with strategic adjustments in response to market dynamics, tariff impacts, and a focus on unlocking shareholder value through business separation and product innovation.